Study Notes: Multiple Sclerosis and Myasthenia Gravis

Overview of Multiple Sclerosis (MS)

  • Definition: A chronic, progressive, and degenerative central nervous system (CNS) disorder characterized by the demyelination of nerve fibers in the brain and spinal cord.

  • Demographics: Onset typically occurs between ages 20-4020\text{-}40. The condition is 2-3×2\text{-}3\times more likely to occur in women.

  • Disease Patterns: MS is marked by a remission and exacerbation pattern. The pace of progression is highly variable.

Pathophysiology and Manifestations of MS

  • Pathophysiology: Autoimmune T-cell activation leads to CNS inflammation and demyelination, which slows nerve impulses. This results in gliosis (plaque formation) and potentially irreversible axon damage in late stages.

  • Visual Symptoms: Includes nystagmus, diplopia, and blurred vision.

  • Motor and Sensory Symptoms: Weakness, spasticity, ataxia, intention tremors, and Lhermitte’s sign (electric shock-like sensations running down the back/limbs upon neck flexion).

  • Other Manifestations: Fatigue (major symptom), cognitive impairment, bowel/bladder dysfunction, and sexual dysfunction.

Diagnostic Criteria and Types of MS

  • Disease Types:     * Relapsing-remitting (85%85\%).     * Primary-progressive (10%10\%).     * Secondary-progressive.     * Progressive-relapsing (5%5\%).

  • Diagnostic Tools: MRI is the test of choice to reveal MS lesions. Other tests include Lumbar Puncture (to check for ↑WBCs\uparrow\text{WBCs} or proteins) and Evoked Potential tests.

  • Clinical Diagnosis requirements:     * Two or more episodes of exacerbation separated by 1 month1\,\text{month} and lasting more than 24 hours24\,\text{hours}.     * History of exacerbations and remissions followed by progression over at least 6 months6\,\text{months}.     * Slow, stepwise progression over at least 5 months5\,\text{months}.

MS Collaborative Care and Interventions

  • Drug Therapy Goals: Modify the disease process, treat acute exacerbations, and manage symptoms.

  • Nonpharmacologic Care: Includes Physical and Occupational Therapy (strengthening exercises, mobility aids) and counseling.

  • Self-Care Education:     * Avoid triggers like infection, trauma, and stress.     * Environmental control: Avoid extreme heat; use air conditioning or tepid baths.     * Energy conservation: Rest to reduce fatigue.

Overview of Myasthenia Gravis (MG)

  • Definition: Meaning “grave muscle weakness,” MG is an autoimmune disease of the neuromuscular junction where antibodies destroy acetylcholine (ACh) receptors.

  • Characteristics: Skeletal muscle weakness that worsens with use throughout the day and improves with rest. It often originates in the face, neck, and jaw before affecting limbs.

  • Progression: Severity varies from mild motor disturbances to respiratory failure. Approximately half of patients present with vision problems.

Diagnosis and Clinical Manifestations of MG

  • Symptoms: Ptosis (drooping eyelids), diplopia, bulbar symptoms (chewing/swallowing/speech difficulty), and proximal limb weakness.

  • Bedside Tests:     * Tensilon (Edrophonium) test: Acetylcholinesterase inhibitor that improves ptosis symptoms within 30-45 secs30\text{-}45\,\text{secs}.     * Ice pack test: Placing ice on the eyelid for 2 minutes2\,\text{minutes} improves ptosis by enhancing transmission at lower temperatures.

  • Diagnostic Studies: Serologic tests for Acetylcholine receptor (AChR-Ab) and Muscle-specific tyramine kinase (MuSK) antibodies. Repetitive nerve stimulation (RNS) shows a progressive decline in response amplitude.

Management of Myasthenia Gravis

  • Short-Term Treatments:     * Intravenous immunoglobulin (IVIG): Dials down the immune system's antibody production.     * Plasmapheresis: Plasma exchange to remove antibodies (typically 66 exchanges over a 2-week2\text{-}week period).

  • Surgical Management: Thymectomy is often performed early (within 2 years2\,\text{years} of onset) because the thymus gland enhances AChR antibodies.

  • Nursing Care: Monitor respiratory status, time medications for peak effect during meals, and provide small, frequent, semi-solid meals to prevent aspiration.

Differentiating Myasthenic and Cholinergic Crises

  • Common Features: Restlessness, dyspnea, dysphagia, and respiratory failure.

  • Myasthenic Crisis: Caused by underdosing or infection. Symptoms improve with the Tensilon test. Features include ↑V.S.\uparrow\text{V.S.} and bowel/bladder incontinence.

  • Cholinergic Crisis: Caused by overdosing on anticholinesterase drugs. Symptoms worsen with the Tensilon test. Features include flaccid paralysis and hypersecretions (saliva, sweat, tears).